This page sets out the radiotherapy platforms, equipment configuration, care pathway and representative cases that the hospital's own promotional material discloses publicly. All copy is transcribed item by item without rewriting; every statement about treatment outcomes is the hospital's own wording and we make no promise on its behalf. Equipment is listed in the order of the hospital's brochure, and cases are grouped by treatment machine with before-and-after imaging.
The hospital's installed equipment has reached an internationally leading level and forms four major platforms: diagnostic imaging, tumour radiotherapy, comprehensive tumour treatment and precision testing.
There are over 20 sets of imaging equipment for medical imaging and nuclear medicine imaging. All imaging results can be used for image fusion, truly achieving accurate radiotherapy for multi-modal biological target delineation.
Jinshazhou Hospital has established the radiotherapy system in accordance with international standards and installed advanced radiotherapy equipment. Besides, the upcoming proton radiotherapy system has obtained the configuration certificate, and has a complete medical equipment quality control system and information management system.
Inclusive of the Da Vinci Robotic Surgery System, DSA Hybrid operating room, blood tumor transplantation cabin, Argon-helium knife cryoablation treatment system, Hifu ultherapy treatment system, acousto-optic Dynamic therapy system, the sixth generation BSD deep tumor phased array hyperthermia system and other equipment.
Our Biological and Chemical Testing laboratory has reached the ISO15189 standard and the American CAP quality standard. More than 2,600 various inspections can be carried out for companion diagnosis and supplementary diagnosis of tumors.
The centre has a long-term partnership with Australia's ICON Group and has built an international medical team that brings together Chinese and foreign medical specialists. The centre has 2,113 staff, including 1,511 professional and technical personnel, 77 holding full senior professional titles, 103 holding associate senior titles and 422 holding intermediate titles (as at September 2025). The oncology medical centre is built to the standards of China's top-tier (Grade 3A) specialist oncology hospitals and of leading medical institutions, as a modern China–Australia joint oncology treatment centre.
The multidisciplinary tumour board (MDT) model brings together specialists from surgical oncology, medical oncology, radiotherapy, radiology, pathology and other relevant departments in a working group that proposes the best treatment plan for each patient through regular consultation. The radiotherapy workflow the hospital publishes, together with the estimated time for each stage, is set out below.
Patients are consulted by radiation oncology specialists to determine the treatment plan.
Scanning and patient immobilization are completed on the simulation CT as the basis for treatment plan design.
Delineate the target volume and organs at risk, and complete dose calculation and plan optimization.
Reposition according to the treatment plan and verify the position and dose.
Deliver irradiation in fractions according to the plan.
Post-treatment rehabilitation guidance and regular follow-up examinations.
The equipment below is listed in the order of the hospital's brochure. For each machine, the "What is it", "Indications" and "Advantages" text is the hospital's own wording, transcribed verbatim by this site without verification or endorsement; whether it applies to a patient must be judged independently by the treating physician on the basis of an in-person examination.
The CyberKnife, also known as the "three-dimensional stereotactic radiosurgery robot". The sixth generation of Accuray CyberKnife (M6) imported by our hospital is a fully digitalized whole-body stereotactic X-ray radiosurgery treatment device with a fully targeted multi-leaf grating. It belongs to the category of stereotactic radiotherapy (SRS/SBRT), which can track the patient's position, tumor location, and patient respiratory motion feedback from three-dimensional directions during treatment. During the treatment process, it can make real-time corrections to the irradiation direction based on medical imaging guidance for the patient's tumor target area (such as tumors).
The TomoTherapy system imported by our hospital integrates IMRT (Intensity-Modulated Radiation Therapy), IGRT (Image-Guided Radiation Therapy), and DGRT (Dose-Guided Radiation Therapy). Its innovative design seamlessly combines a linear accelerator with helical CT, overcoming many limitations of traditional accelerators. With CT guidance, it delivers 360° focal layer irradiation to tumors, enabling efficient and precise treatment for malignant tumor patients.
The TrueBeam system imported by our hospital is currently the world's most advanced new generation linear accelerator. This system can be used for image-guided radiotherapy and radiosurgery, and is equipped with the new generation of HyperArc technology. Its precise and efficient core features greatly improve the speed and accuracy of tumor treatment, making the device capable of meeting the treatment needs of various radiotherapy techniques and different diseases.
The Halcyon system imported by our hospital is the world's first medical linear accelerator that achieves 100% image guidance and features full digitalization and artificial intelligence. With the advantages of high integration, high automation, and high intelligence, it is a powerful tool for treating tumors, further elevating radiotherapy from traditional "precision radiotherapy" to "intelligent precision radiotherapy".
The latest fifth-generation product GammaMedplus™ iX from the American company Varian, introduced by our hospital, is a device specially designed for three-dimensional conformal brachytherapy. Afterloader therapy, also known as brachytherapy, internal radiation therapy, and sealed source radiation therapy, can be a stand-alone treatment or be combined with other treatments such as surgery, external radiation therapy, and chemotherapy to achieve a complementary effect. It uses the natural orifice of the human body (such as the vagina) or inter-tissue insertion to introduce radioactive sources into the body for precise direct irradiation of tumors. It can not only better improve the patient's quality of life and increase the survival rate, but also effectively reduce the risk of local recurrence rate and prolong patient survival.
The Ethos system imported by our hospital is the world's first online adaptive radiotherapy system based on artificial intelligence technology. It builds upon conventional linear accelerators by incorporating cutting-edge technologies such as artificial intelligence, multimodal high-definition imaging, efficient imaging scanning, and online quality control systems, enabling efficient online adaptive radiotherapy.
This device achieves the industry's highest multi-layer large-aperture CT, fastest rotation speed, optimal image resolution, and maximum HD FOV (high-definition field of view). In terms of both image quality and accuracy, it enables precise contour delineation and is the basis for precise plan design and treatment, quickly and accurately completing image acquisition for all parts of the body and different positions.
Siemens' MR-only radiotherapy solution enables direct generation of "synthetic CT" images from high-resolution MRI data, completely eliminating radiation exposure. This approach is particularly valuable for pediatric and pregnant patients, and those requiring repeated treatment courses. With a single MRI scan, clinicians achieve both precise target delineation and accurate radiation dose calculation, removing the need for CT simulation and streamlining the entire radiotherapy workflow. This technology is primarily implemented for tumors in the head and pelvic regions.
Prior to treatment, an MRI simulation scan is performed to re-confirm the tumor's position and morphological changes. The radiation oncologist then modifies the target volume accordingly. A rapid planning process is used to re-optimize the treatment plan. Finally, the patient is transferred to the linear accelerator via a shuttle couch, which ensures their position remains unchanged throughout the process. The complete process takes under 25 minutes.
The high-performance, form-fitting exclusive blanket-style AIR Coil delivers unmatched image quality. The Premier model incorporates a new coil material with an INCA fiber loop design, marking a revolutionary breakthrough that makes MRI coils lighter and more flexible. The lightweight, high-channel design of the AIR Coil simplifies radiotherapy patient positioning and significantly improves the visualization of small lesions and tissue boundary sharpness, achieving optimal imaging quality.
The Department of Nuclear Medicine of Jinshazhou Hospital of Guangzhou University of Chinese Medicine boasts a skilled and dedicated team of physicians, nurses, and technologists who are committed to clinical excellence, education, and research. It provides comprehensive nuclear medicine imaging diagnostics and radionuclide therapy. Currently, the department has a total of 37 staff members.
Recognized as one of the earliest examples of targeted therapy, molecular imaging, and theranostics, I-131 therapy constitutes an essential element in the triple-therapy regimen for DTC ("surgery + I-131 therapy + TSH suppression"). The clinical portfolio of our department encompasses the application of I-131 SPECT-CT image fusion for diagnosing metastases, as well as molecular targeted therapy for radioiodine-refractory DTC (RAIR-DTC).
This method is characterized by its simplicity, well-established efficacy, low recurrence rate, minimal side effects, and high safety profile. It is particularly suitable for patients with significantly enlarged thyroids, as well as those for whom antithyroid drug (ATD) therapy has been ineffective, has resulted in relapse, or has caused adverse effects such as leukopenia, liver impairment, or allergic reactions.
This method is primarily used for the treatment of keloids and infantile hemangiomas. The procedure is characterized by its simplicity, safety, and proven efficacy.
This treatment is primarily used to alleviate cancerous pain caused by bone metastases from malignant tumors (such as prostate cancer, breast cancer, lung cancer, etc.). Its main advantage is the long duration of pain relief.
This treatment is primarily indicated for unresectable malignant liver tumors, such as colorectal cancer liver metastases and primary hepatocellular carcinoma. The therapeutic process begins with a pre-treatment planning phase involving nuclear medicine SPECT-CT mapping to assess the patient's suitability for treatment and calculate the therapeutic dosage. Subsequently, the Y-90 resin microspheres are delivered directly to the target tumors via the hepatic artery during an interventional radiology procedure. The tumors are then destroyed by the beta radiation emitted by the Y-90. (The hospital has 4 Y-90 observation wards.)
The PET Radiopharmacy Center at the Department of Nuclear Medicine of Jinshazhou Hospital of Guangzhou University of Chinese Medicine is a fully integrated facility for the production and research of positron-emitting radiopharmaceuticals. Operating under full-process Good Manufacturing Practice (GMP) compliance—from its design and construction to daily management—the center is officially licensed by the Guangdong Provincial Medical Products Administration with a "Radioactive Drug Use License (Type 4)" and a "Filing Approval for Positron-emitting Radiopharmaceuticals." The center's infrastructure includes a GMP cleanroom, a cyclotron vault and control room, synthesis hot cells, a quality control (QC) lab, and a small animal lab. Its core equipment is a Sumitomo HM-10HC+ medical cyclotron (10 MeV), equipped with six targets (18F, 11C, 13N, 68Ga, 64Cu, 89Zr), including solid targets for 68Ga, 64Cu, and 89Zr. Currently producing and developing 39 different positron-emitting radiopharmaceuticals, the center serves as a crucial platform for clinical diagnostics and drives the research and clinical translation of novel radiopharmaceutical agents.
13 cases are grouped by treatment machine, with before-and-after imaging published by the hospital. All diagnoses, doses and follow-up results are transcribed from the hospital's own text; an individual result does not mean that similar conditions will all achieve the same result. Imaging is taken from the hospital's public material, Used with the hospital's permission · patient information de-identified.
The content and imagery above are taken from Official material of Jinshazhou Hospital of Guangzhou University of Chinese Medicine · Radiotherapy Oncology Center and are material the hospital has publicly disclosed. Terms such as "first case", "complete disappearance" and "marked shrinkage" are the hospital's own wording; this site transcribes them verbatim without verification or endorsement. The procedure, dose and outcome of an individual case all depend on stage, pathological type, underlying disease and response to treatment, and none of this constitutes medical advice, a promise of efficacy or a guarantee of future results. Any diagnostic or treatment decision must be made independently by a qualified medical institution and a licensed physician on the basis of the patient's in-person examination results.
Submit the diagnostic, pathology and imaging documents you already have from a Malaysian hospital and we will help check the disease area, equipment suitability and the receiving hospital's arrangements. The platform provides standardised record preparation, bilingual medical translation and coordination with Chinese hospitals; the treatment plan is determined independently by the treating physician team at the receiving hospital.
